Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
FENTANYL
Neurology & Sedation · Neurology & Sedation · Level 1
|
MORPHINE
Neurology & Sedation · Neurology & Sedation · Level 1
|
|---|---|---|
| Mechanism of action | Binds primarily to inhibitory G-protein-coupled μ-opioid receptors → inhibits adenylyl cyclase → ↓ cAMP → opens K+ channels and inhibits presynaptic voltage-gated Ca2+ channels → hyperpolarisation and ↓ neurotransmitter release Binds primarily to inhibitory G-Protein Coupled μ-opioid receptors→ ↑adenylyl cyclase→ ↓cAMP→ hyperpolarization of cell→↓neurotransmitter release |
Binds primarily to inhibitory G-Protein Coupled μ-opioid receptors→ ↑adenylyl cyclase→ ↓cAMP→ hyperpolarization of cell→↓neurotransmitter release |
| Physiological effects | inhibitory action, less likely to ppt histamine release |
CNS: PNS Excitatory action |
| Absorption | IV/IM/TD. BA PO 30%SL50%skin>90% |
PO/IV/IM/SC/SL/IT |
| Distribution | relative lipid sol 500 Rapid redistribution |
relative lipid sol 1 but crosses BBB pKa 8.0 (25% unionised) |
| Protein binding | prot bind 80-85% |
prot bind 20-40% (Alb) |
| Volume of distribution | Mod Vd 4-6L/kg |
mod Vd 3-4L/kg |
| Metabolism | Slow Hepatic, primarily via CYP3A4clearance |
Metabolised to morphine-3-glucuronide (70%) |
| Excretion | excretion Urine 75% |
Excreted mainly in urine as conjugates with 10% in faeces |
| Half-life | half life I.V.: 2-4 hours, prolonged context sensitive half time |
Half time 2-4hrs (large interpatient Variability) |
| Adverse Effects Toxicity | Respiratory depression including postoperative recurrence. Bradycardia. Chest-wall rigidity. Nausea and vomiting. Dependence. Decreased gastrointestinal motility. Similar to other opioids. Differences due to lipid sol. Similar. Differences due to lipid sol. |
CNS: dysphoria, confusion, ↓LoC, ↓cough reflex, miosis(PNS) |
| Class Group | Opiate Analgesic |
Opiate Analgesic |
| Indications Uses | 1. to provide the analgesic component in general anaesthesia |
1. for premedication |
| Introduction | Tertiary amine which is a synthetic phenylpiperidine derivative |
naturally occuring phenanthrene derivative from papaver somniferum plant |
| Legacy Cicm Level | Level 1 |
Level 1 |
| Main Action | μ receptor agonist |
primarily CNS μ receptor activity, also κ and δ. |
| Presentation | colourless solution 50mcg/ml, TDpatch (25mcg-100mcg/hr) and as lozenges |
either as a clear liquid for injection, orally in immediate (liquid or tablet) and sustained release (MS Contin) |
| Route And Dose | Bolus: 1-2 mcg/kg (relative potency 50-100) |
Dose 5-10mg titrate eff¬ect, may increase x100 with tolerance (relative potency 1) |
| Special Points | - Incompatible with thiopental - Dialysis - unknown |
May precipitate encephalopathy in hepatic failure Good reversal with naloxone (does not affect epidural analgesia) Not removed by haemo/peritoneal dialysis |